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A 63-year-old Taiwanese man with a history of cutaneous melanoma presented with a rapid onset of
bilateral shimmering light and blurred vision. A fundoscopic examination was normal. However, visual
ﬁeld examination indicated generalized depression in both eyes. Scotopic rod-speciﬁc electroretinog-
raphy (ERG) was undetectable and scotopic maximal combined-cone and rod-speciﬁc ERG showed the
characteristics of negative ERG (a normal a-wave and a diminished b-wave, with the b-wave smaller than
the a-wave), indicating dysfunction of the bipolar cells. Melanoma-associated retinopathy (MAR) was
suspected and a systemic work-up gave a diagnosis of metastatic melanoma. This case shows the typical
presentation of MAR. Greater awareness of MAR in patients with unexplained visual loss may help to
identify an occult focus of metastatic melanoma.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Paraneoplastic syndromes are caused by the immunological
effects of a neoplasm located in a remote position away from the
affected organ. Melanoma-associated retinopathy (MAR) is a par-
aneoplastic retinal disorder occurring in patients with cutaneous
melanoma. Other paraneoplastic syndromes associated with vision
loss include cancer-associated retinopathy, paraneoplastic optic
neuropathy, and bilateral diffuse uveal melanocytic proliferation.
MAR was ﬁrst reported and suggested to be a paraneoplastic
phenomenon by Berson and Lessell,1 who reported a night blind-
ness syndrome in a patient with a pre-existing diagnosis of cuta-
neous melanoma. MAR has a sex ratio of 4.5:1 skewed towards
men. Most patients only present years after the primary diagnosis
of melanoma. The average latency from diagnosis of melanoma to
recognition of MAR is 3.6 years.2 Patients typically develop a sud-
den onset of ﬂickering shimmering lights that begins from months
to years after the diagnosis of melanoma. They often report night
blindness, progressive loss of vision, and visual ﬁeld constriction.3
Ophthalmoscopic ﬁndings are usually minimal, although retinal
pigment epithelial irregularity, retina arteriolar attenuation, and
optic disc pallor have been reported. MAR is characterized by
electronegative electroretinography (ERG) and dysfunction of theof interest.
logy, Chang Gung Memorial
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un).
e Ophthalmologic Society of TaiwON response bipolar cells, which is similar to the pattern in
congenital stationary night blindness.
The incidence of melanoma varies worldwide, with a higher
prevalence in highly pigmented individuals. Malignant melanoma
is very rare in the Taiwanese population, with an incidence rate of
0.65/100,000.4To our knowledge there has been no previous report
of MAR in Taiwan. We present here the case of a patient with MAR
syndrome together with the corresponding electrophysiological
measurements.
2. Case report
A 63-year-old Taiwanese man presented at our hospital in
December 2011 reporting a rapid onset of blurred vision in both
eyes. In addition, he reported shimmering light, poor side vision,
and diminished visual acuity in low light environments. A general
review indicated a previous history of cutaneous malignant mela-
noma on his left forefoot, with a Breslow thickness of 4.24 mm and
a Clark level IV, which was ﬁrst diagnosed in May 2009. A previous
computed tomography scan gave negative results for metastatic
disease. The wide local excision showed clear surgical margins and
sentinel node biopsy was declined.
An ophthalmic evaluation showed that the best corrected visual
acuity was 20/20 in the right eye and 20/28 in the left eye. A slit
lamp examination, intraocular pressure, and fundus examination
were all normal for both eyes (Fig. 1). The Humphrey ﬁeld analyzer
showed marked generalized depression in each eye (Fig. 2). Fluo-
rescein angiography was normal, except for dye leakage on the left
optic disc (Fig. 3).an. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A,B) Fundus photographs of a patient with melanoma-associated retinopathy. The fundi appear normal in both eyes.
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maximal combined-cone and rod-speciﬁc ERG showed an electro-
negative waveform in which the a-wave was normal, indicating
normal phototransduction. The b-wave was so markedly reduced
that the b-wave was smaller than the a-wave, suggesting
dysfunction of the bipolar cells. The photopic ERG had a broad a-
wave followed by a b-wave and lacked photopic oscillary potentials.
The results of the long-duration ONeOFF ERGs showed a normal a-
wave, a selectively diminished ON b-wave, and a preservation of
the OFF d-wave, which further conﬁrmed the involvement of
depolarizing ON-bipolar cells (Fig. 4).
An initial diagnosis of MARwas considered. Full-body computed
tomography and positron emission tomography scans showed local
recurrence with regional, distant lymph nodes, liver, and bone
metastases (Fig. 5). The patient began a course of biochemotherapy
with interleukin 2 and dacarbazine in December 2011.
ERGs and visual ﬁeld examination recorded 3 months after
biochemotherapy treatment showed no signiﬁcant change fromFig. 2. Perimetric ﬁndings in a patient withe initial results. During the ﬁnal visit in February 2012, visual
acuity was correctable to 20/25 in the right eye and 20/50 in the left
eye. Spectral domain ocular coherent tomography showed a normal
retinal structure (Fig. 6).
3. Discussion
Early diagnosis of MAR can be difﬁcult as a result of subtle
clinical ﬁndings. ERG is extremely sensitive in detecting abnor-
malities associated with MAR. In ERG, a negative waveform (a-
wave) represents the response of the photoreceptors, followed by a
positive waveform (b-wave) generated by a combination of cells in
the Müller/bipolar layer. MAR is characterized by an electronega-
tive waveform, with a normal a-wave and a selectively reduced b-
wave resulting in a b/a ratio of <1.0. These ERG changes imply
dysfunction of the second-order neurons.5 The rod-speciﬁc and
cone- speciﬁc a-wave amplitudes and implicit times are relatively
normal, which reﬂects a normal photoreceptor function.th melanoma-associated retinopathy.
Fig. 3. The results from ﬂuorescence angiography were normal (A,B) except for optic disc staining during the late phase (C,D).
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from the photoreceptors to bipolar cells, and then to the ganglion
cells. The normal cone b-wave responses consist of both ON and
OFF components. The ON pathway transmits information relating
to the onset of light, and the OFF pathway responds to the end ofFig. 4. Full-ﬁeld standard electroretinograms (ERGs) and long duration ONeOFF ERGs. No sc
(red arrows) in scotopic maximal combined-cone and rod-speciﬁc response were noted in ei
OFF d-wave were present in long duration ONeOFF ERGs.light stimulus. The depolarizing bipolar cells drive the ON pathway,
and the hyperpolarizing bipolar cells drive the OFF pathway. In
MAR, the ON pathway is selectively dysfunctional, but the OFF
pathway is preserved. These changes may be caused by either
dysfunction of the ON bipolar cells or by a defect in the synapticotopic rod response and a reduced b-wave amplitude with the shape of a negative ERG
ther eye. Normal a-wave, diminished ON b-wave (black arrows), and preservation of the
Fig. 5. Positron emission tomography whole body scan. The scan showed local disease
recurrence with regional, distant lymph nodes, liver, and bone metastases (arrows).
Fig. 6. Spectral domain ocular coherent tomography showed an overall normal retinal
structure.
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cells.6,7 This is supported by the study of Lei et al,8 which shows
that an intravitreal injection of human MAR immunoglobulin G
implicates the functional disruption of retinal depolarizing bipolar
cell signaling in a monkey model.
Although the pathological process remains poorly understood,
MAR is thought to originate from a B lymphocyte response to the
production of antibodies against an unknown melanoma antigen,
which cross-reacts with retinal components, particularly bipolar
cells.9 A previous study showed a strong family history of autoim-
mune disorders in most patients.10 Examinations of serum for
antiretinal antibodies by Western blot and indirect immunohisto-
logical investigations for a retinal inner nuclear layer and bipolar cell
staining have given evidence for this theory, although the speciﬁc
antibodies involved in MAR have not been systemically examined.
Diagnosing MAR is challenging because of its rarity and subtle
ophthalmoscopic ﬁndings. In addition, the absence of a history of
melanoma cannot rule out MAR because MAR may precede or
follow the diagnosis of melanoma, and is not always associated
with metastatic disease. Unexplained visual loss is a common
reason for referrals of patients to visual function diagnostic labo-
ratories. In this patient, we made the diagnosis mainly by ERG
ﬁndings and clinical history. Unfortunately, we did not perform the
serum test for antiretinal antibodies, nor immunohistochemistry to
conﬁrm the diagnosis.Decreasing the tumor burden by cytoreductive surgery and
adjuvant immunotherapy may result in the elimination of the
associated antiretinal antibodies and the improvement of retinal
function. There are concerns, however, that immunomodulatory
treatment may increase the rate of death from cancer because
patients with MAR may have antibodies that protect against the
spread of tumors. However, Keltner et al2 reported no difference in
survival rates between treated and untreated patients. In addition,
local periocular steroid treatment may improve visual function by
stabilizing the outer retinal dysfunction from the autoantibodies,
although the number of cases reported is limited.11 Other treat-
ments, including systemic steroids and plasmaphoresis, have also
been reported to improve visual symptoms, but the long-term ef-
fects still need to be determined. Our patient was treated with
interleukin 2 and dacarbazine biochemotherapy, but the results
from ERG, visual ﬁeld examination, and his vision showed no sig-
niﬁcant change 3 months after treatment.
Electrodiagnostic tests remain pivotal to objectively evaluate
retinal function in the diagnosis of MAR. Serum testing for antiretinal
antibodies and indirect immunohistological investigations can
further conﬁrm the diagnosis. Full-body imaging should be per-
formed insuspected casesofMAR.Despite the rarityof this syndrome,
it is important to have a greater awareness of its associationwithMAR
to allow timely diagnosis and the treatment of future patients.
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